Conolidine’s analgesic consequences stem from its conversation with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors while in the central anxious program, conolidine modulates alternate molecular targets. A Science Advancements study observed that conolidine interacts With all the atypical chemokine receptor ACKR